Candida

Dosage for Astragalus Nuttallii Leaf is highly individualized and must be determined through a meticulous titration process. There is no 'standard' dose, as sensitivity varies by several orders of magnitude between patients.

• Diagnostic Testing (Skin Prick): Typically, a concentration of 1:10 or 1:20 w/v (weight/volume) is used. A single drop is applied to the skin, followed by a puncture.
• Immunotherapy Build-up Phase: Treatment usually begins with a very dilute solution (e.g., 1:100,000 or 1:1,000,000 w/v). Injections are administered once or twice weekly, with the dose increasing by 20% to 50% at each visit, provided no significant local or systemic reactions occur.
• Maintenance Phase: Once the 'Maintenance Dose' is reached (the highest dose tolerated by the patient that provides symptomatic relief, often 0.5 mL of a 1:100 or 1:10 w/v solution), the interval between injections is increased to every 2 to 4 weeks.

Astragalus Nuttallii Leaf may be used in children, typically those aged 5 years and older who can cooperate with the injection schedule and report symptoms.

• Dosing Logic: Pediatric dosing follows the same escalation and maintenance protocols as adult dosing, though initial concentrations may be even more conservative in highly atopic children.
• Safety: Children must be monitored even more closely for signs of systemic distress, as they may not be able to articulate early symptoms of anaphylaxis (e.g., itchy throat or 'sense of doom').

Renal Impairment

No specific dosage adjustments are required for renal impairment, as the proteins are primarily degraded by proteases. However, patients with severe renal disease may have altered fluid balance, which should be considered if systemic reactions occur.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment. The clearance of allergenic extracts does not rely on hepatic CYP450 metabolism.

Elderly Patients

Geriatric patients may have a higher prevalence of cardiovascular disease. Because the management of a systemic reaction requires the use of epinephrine (an adrenergic agonist), the risk-benefit ratio must be carefully weighed in patients for whom a sudden increase in heart rate or blood pressure could be dangerous.

• Administration Route: This medication is for subcutaneous injection ONLY. It must never be given intravenously, as this significantly increases the risk of fatal anaphylaxis.
• Injection Site: Usually administered in the posterior aspect of the upper arm. Sites should be rotated between the left and right arms to minimize local tissue changes.
• Observation Period: Patients MUST remain in the physician's office for at least 30 minutes after every injection. Most fatal reactions occur within this window.
• Storage: Store the extract in a refrigerator between 2°C and 8°C (36°F to 46°F). Do not freeze. Discard if the solution becomes turbid or shows precipitation.

If a dose is missed during the build-up phase, the next dose may need to be reduced rather than increased to maintain safety.

• 1 week late: Repeat the previous dose.
• 2 weeks late: Reduce the dose by 1 to 2 escalation steps.
• 3+ weeks late: Consult the prescribing allergist; the build-up may need to be restarted from a much lower concentration.

An 'overdose' in the context of allergenic extracts usually refers to the administration of a dose higher than the patient's current tolerance level, leading to a systemic reaction.

• Signs: Hives (urticaria), swelling (angioedema), wheezing, shortness of breath, hypotension (low blood pressure), and loss of consciousness.
• Emergency Measures: Immediate administration of Epinephrine (0.3mg IM for adults), application of a tourniquet above the injection site to slow absorption, and emergency transport to a hospital.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Local reactions are the most frequent side effect of Astragalus Nuttallii Leaf administration. These are generally considered a normal part of the body's immune response to the extract.

• Local Erythema: Redness at the injection site, which may appear immediately or several hours later.
• Local Swelling (Wheal): A raised, itchy bump at the site of injection. If the swelling is smaller than the size of a half-dollar (approx. 3 cm), it is usually managed with topical cold packs.
• Pruritus: Intense itching at the injection site that typically resolves within 24 hours.

• Large Local Reactions (LLR): Swelling that exceeds 5 cm in diameter. While not dangerous themselves, LLRs can be a predictor of future systemic sensitivity and may require a dosage plateau or reduction.
• Fatigue: Some patients report feeling unusually tired for several hours following an immunotherapy injection.
• Headache: Mild to moderate tension-type headaches have been reported following administration.

• Systemic Urticaria: Hives appearing on parts of the body distant from the injection site.
• Rhinitis Flare: A temporary worsening of sneezing or nasal congestion shortly after the injection.
• Vasovagal Reaction: Fainting or lightheadedness due to the needle stick rather than the extract itself.

> Warning: Stop taking Astragalus Nuttallii Leaf and call your doctor immediately if you experience any of these.

• Anaphylaxis: A life-threatening, multi-system allergic reaction. Symptoms include a rapid drop in blood pressure, fainting, and severe respiratory distress.
• Laryngeal Edema: Swelling of the throat or larynx, leading to difficulty swallowing or a high-pitched sound when breathing (stridor).
• Bronchospasm: Sudden constriction of the airways causing severe wheezing and inability to catch one's breath.
• Hypotension: A dangerous drop in blood pressure that may lead to shock.
• Angioedema: Deep tissue swelling, particularly of the face, lips, tongue, or eyes.

• Subcutaneous Nodules: Small, firm lumps under the skin at the site of repeated injections. These are usually benign but should be monitored.
• Persistent Sensitization: In rare cases, immunotherapy can inadvertently increase a patient's sensitivity to the allergen if the build-up is managed incorrectly.
• Arthus Reaction: A Type III hypersensitivity reaction characterized by localized tissue vasculitis and necrosis, though this is extremely rare with modern purified extracts.

WARNING: RISK OF SEVERE ALLERGIC REACTIONS

Astragalus Nuttallii Leaf extract can cause severe, life-threatening systemic reactions, including anaphylaxis. Because of this risk, the following conditions apply:

1. 1Supervision: This drug must only be administered by healthcare providers experienced in the management of anaphylaxis.
2. 2Observation: Patients must be observed for at least 30 minutes in the office after each injection.
3. 3Pre-existing Conditions: Patients with unstable asthma are at a significantly higher risk for fatal reactions and should not receive immunotherapy until their asthma is well-controlled.
4. 4Epinephrine: Patients should be prescribed and trained in the use of an epinephrine auto-injector to carry with them at all times during treatment.

Report any unusual symptoms to your healthcare provider.

Astragalus Nuttallii Leaf is a potent biological product. Its use is restricted to patients with a clear clinical history of allergy and confirmed IgE sensitivity. It is not a general 'immune booster' and should never be used without specific diagnostic evidence of Nuttall's Milkvetch allergy.

No FDA black box warnings for Astragalus Nuttallii Leaf are currently listed in the same format as small-molecule drugs; however, all allergenic extracts carry a prominent 'Warning' section regarding anaphylaxis and the requirement for physician supervision. The risk of death from allergenic extract injection is estimated at 1 in 2.5 million injections, according to data from the American Academy of Allergy, Asthma & Immunology (AAAAI).

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. Any factor that lowers the 'allergic threshold'—such as recent exercise, hot showers, or an acute viral infection—can increase the risk of a systemic reaction on the day of the injection.
• Asthma Status: Patients must be screened for asthma symptoms before every injection. If a patient's Peak Expiratory Flow (PEF) is significantly below their personal best, the injection should be deferred.
• Cardiovascular Stability: Patients with significant underlying heart disease may not tolerate the stress of an anaphylactic reaction or the high doses of epinephrine required to treat it.
• Beta-Blocker Use: Patients taking beta-blockers may be resistant to the effects of epinephrine, making the treatment of a systemic reaction extremely difficult.

• Pre-Injection Screening: Assessment of current allergy symptoms, asthma control, and any new medications.
• Post-Injection Observation: 30-minute mandatory wait time with vital sign monitoring if the patient feels unwell.
• Spirometry: Periodic lung function tests for patients with co-morbid asthma.
• Skin Test Reactivity: Periodic re-testing (every 2-3 years) to assess the progress of desensitization.

Generally, Astragalus Nuttallii Leaf does not cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have been fully cleared by a medical professional and the effects of the emergency medications have worn off.

Alcohol consumption should be avoided on the day of the injection. Alcohol can cause vasodilation (widening of blood vessels), which may increase the rate of allergen absorption and potentially lower the threshold for a systemic reaction.

Immunotherapy is typically a 3-to-5-year commitment. Stopping prematurely often results in the return of allergic symptoms. There is no 'withdrawal syndrome' associated with stopping Astragalus Nuttallii Leaf, but the immunological benefits will gradually diminish over time if the maintenance phase is not completed.

> Important: Discuss all your medical conditions with your healthcare provider before starting Astragalus Nuttallii Leaf.

• Beta-Adrenergic Blockers (e.g., Propranolol, Atenolol): These are strictly contraindicated in most immunotherapy protocols. If a patient experiences anaphylaxis, beta-blockers prevent epinephrine from working on the heart and lungs, potentially leading to a fatal outcome. The interaction is a pharmacodynamic antagonism where the beta-blocker prevents the life-saving adrenergic agonist from binding to its receptors.

• ACE Inhibitors (e.g., Lisinopril): These medications may interfere with the body's ability to degrade kinins during an allergic reaction, potentially making an anaphylactic event more severe and harder to treat.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effect of the catecholamines (like epinephrine) used to treat reactions, leading to a hypertensive crisis (dangerously high blood pressure).
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can increase the sensitivity of the cardiovascular system to adrenergic agonists, complicating the management of a systemic reaction.

• Other Allergenic Extracts: Receiving multiple different extracts (e.g., grass, mold, and Astragalus) on the same day increases the cumulative 'allergic load' on the immune system, raising the risk of a systemic reaction.
• Systemic Corticosteroids: While they treat allergies, long-term use can mask the early warning signs of an escalating allergic response during the build-up phase.

• High-Fat Meals: No direct interaction with the extract, but heavy meals immediately before an injection may complicate the management of gastrointestinal symptoms during anaphylaxis.
• Caffeine: High doses of caffeine may increase heart rate, which could be confused with early signs of an allergic reaction or potentiate the side effects of epinephrine.

• St. John's Wort: May have unpredictable effects on the vascular system's response to inflammatory mediators.
• Ginkgo Biloba: Known for its anti-platelet effects, it could theoretically increase bruising at the injection site, though this is not clinically significant for most patients.

• Skin Tests: Antihistamines (H1 blockers) must be discontinued 3 to 7 days before skin testing with Astragalus Nuttallii Leaf, as they will suppress the wheal and flare response, leading to a false-negative result.
• Serum IgE Tests: Immunotherapy will cause a transient rise in specific IgE followed by a long-term decline; this must be interpreted correctly by the clinician.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Astragalus Nuttallii Leaf must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: Patients with an FEV1 (Forced Expiratory Volume) consistently below 70% of predicted are at an unacceptably high risk for fatal bronchospasm during immunotherapy.
2. 2Recent Myocardial Infarction: Patients who have had a heart attack within the last 3-6 months cannot tolerate the cardiovascular stress of a systemic reaction or the epinephrine used to treat it.
3. 3History of Severe Anaphylaxis to this Specific Extract: If a patient has previously had a near-fatal reaction to Astragalus Nuttallii Leaf, the risks of continuing treatment usually outweigh the benefits.
4. 4Beta-Blocker Therapy: As detailed in the interactions section, the inability to respond to epinephrine is an absolute contraindication in most clinical settings.

• Pregnancy: While maintenance doses can often be continued, starting a new build-up phase during pregnancy is generally avoided due to the risk of maternal anaphylaxis causing fetal hypoxia (lack of oxygen to the baby).
• Autoimmune Diseases: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may experience a flare of their condition when the immune system is stimulated with allergenic extracts.
• Malignancy: Patients with active cancer may have altered immune responses, and the priority of treatment usually shifts away from elective allergy management.

Astragalus Nuttallii is a member of the Fabaceae (Legume) family. Patients with known severe allergies to other legumes (such as peanuts, soy, or other Astragalus species) may exhibit cross-reactivity. Extreme caution should be used during initial skin testing in these individuals.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Astragalus Nuttallii Leaf.

Astragalus Nuttallii Leaf is generally classified as Pregnancy Category C.

• Risk Summary: There are no adequate and well-controlled studies in pregnant women. The primary risk is not the extract itself (which is a natural protein), but the potential for a systemic reaction in the mother. Anaphylaxis can lead to uterine contractions and placental insufficiency, endangering the fetus.
• Clinical Practice: Allergists typically do not initiate immunotherapy during pregnancy. If a patient is already on a stable maintenance dose and is tolerating it well, the treatment may be continued at that dose (without further escalation) at the physician's discretion.

It is not known whether the protein components of Astragalus Nuttallii Leaf are excreted in human milk. However, because these are large proteins that are degraded in the mother's system, they are unlikely to reach the infant in an intact, sensitizing form. Breastfeeding is generally not considered a contraindication for continuing immunotherapy.

Immunotherapy with Astragalus Nuttallii Leaf is generally not recommended for children under the age of 5.

• Reasons: Younger children may have difficulty communicating the early symptoms of a systemic reaction. Furthermore, the long-term benefit-risk profile is best established in school-aged children.
• Growth Effects: There is no evidence that allergenic extracts affect growth or development in children.

Patients over age 65 require a careful cardiovascular assessment.

• Pharmacokinetic Changes: While the metabolism of the extract doesn't change, the elderly are more likely to have underlying conditions (like coronary artery disease) that make the use of emergency adrenergic agonists (epinephrine) more hazardous.
• Polypharmacy: The higher likelihood of being on beta-blockers or ACE inhibitors must be thoroughly screened.

No dosage adjustment is needed for patients with kidney disease. However, clinicians should be aware that if anaphylaxis occurs, the management of intravenous fluids and emergency medications must be handled with care in patients with end-stage renal disease (ESRD).

Liver disease does not affect the safety or efficacy of Astragalus Nuttallii Leaf, as the liver is not the primary site of protein allergen degradation.

> Important: Special populations require individualized medical assessment.

Astragalus Nuttallii Leaf acts as an immunomodulator. Its molecular mechanism involves the presentation of Nuttall's Milkvetch antigens by dendritic cells to naive T-cells. In an allergic individual, this normally results in Th2 cell activation. Immunotherapy forces the system toward immune deviation, favoring Th1 cells and Regulatory T-cells (Tregs). The Tregs produce Interleukin-10 (IL-10), which induces B-cells to switch from producing IgE to producing IgG4. IgG4 acts as a 'blocking antibody,' binding to the allergen before it can reach the IgE on mast cells.

• Dose-Response: There is a clear dose-response relationship in immunotherapy; higher doses (within the tolerated maintenance range) generally lead to greater long-term desensitization.
• Time to Onset: Diagnostic skin test results appear in 15-20 minutes. Therapeutic effects (symptom reduction) typically take 6 to 12 months of consistent treatment to become apparent.
• Duration of Effect: If a full 3-to-5-year course is completed, the 'immunological memory' and tolerance can last for many years, or even a lifetime, after discontinuation.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous protein absorption) |

| Protein Binding | High (binds to IgE, IgG, and APC receptors) |

| Half-life | Proteins: Minutes to Hours; Immunologic effect: Years |

| Tmax | 30-60 minutes (for systemic absorption) |

| Metabolism | Extracellular Proteases |

| Excretion | Renal (as amino acids/peptides) |

• Molecular Formula: Complex mixture of proteins (no single formula).
• Molecular Weight: Ranges from 10,000 to over 100,000 Daltons.
• Solubility: Highly soluble in aqueous buffers and saline.
• Structure: Comprised of various plant proteins, including glycoproteins and profilins native to the Astragalus genus.

Astragalus Nuttallii Leaf is a Non-Standardized Plant Allergenic Extract. It is related to other legume-family extracts and is part of the broader therapeutic category of Allergen Immunotherapy (AIT) products.